You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A nanoparticle delivery system for CRISPR/Cas9 based therapeutics
SBC: ATGC Inc. Topic: 100Abstract Applications of customizable nucleases such as CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteinhave enabled efficient and precise gene correction in vitroand hold promises for eventually achieving in vivo gene correction therapyHoweverto apply CRISPR Casin therapeutic settingsseveral major challenges remain to be addressedihomologous recombinatio ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A Subcritical Testbed for Fast Neutron Irradiation of Novel Fuels and Cladding in Fast Reactors
SBC: Niowave, Inc. Topic: 29jRecently, the Generation IV International Forum has established a set of nuclear reactors (advanced nuclear reactors), with main objectives to improve overall reactor safety, efficiency, sustainability, and proliferation resistance for economically viable nuclear energy. These advanced reactor technologies rely on novel fuels and materials that are resistant to radiation damage and corrosive envir ...
STTR Phase II 2018 Department of Energy -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
